May 01, 2025
Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies
Oct 23, 2024
Novo Nordisk to present new cardiometabolic and renal data, including with semaglutide, at Kidney Week 2024, ObesityWeek®, The Liver Meeting®, and AHA Scientific Sessions 2024
Nov 05, 2020
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioral therapy
Apr 14, 2020
Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19
Apr 02, 2020
Coronavirus (COVID-19) resources available from Novo Nordisk in the US
Feb 08, 2018
Novo Nordisk Launches Rebinyn® in the United States for People with Hemophilia B
Feb 05, 2018
Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes
Jan 08, 2018
New disposal option for California residents using Novo Nordisk medicines and needles
Dec 05, 2017
Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes
Nov 14, 2017
Anthony Anderson, Star of ABC's "black-ish," Partners with Novo Nordisk to Launch "Get Real About Diabetes(TM)"
Oct 26, 2017
Global City Leaders: Cut Obesity By A Quarter To Prevent 100M New Diabetes Cases By 2045
Oct 24, 2017
Novo Nordisk and HITLAB Announce Finalists, Teams Edging Closer to $75,000 in Prizes
Oct 18, 2017
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide
Oct 04, 2017
Novo Nordisk and HITLAB Team Up for Fourth Annual Innovators Summit
Sep 26, 2017
Working Mother names Novo Nordisk one of its "100 Best Companies"
Sep 26, 2017
Novo Nordisk Teams Up with HITLAB to Challenge Innovators to Develop Voice-Activated Technology for Diabetes Care with $75,000 in Prizes
Sep 19, 2017
HITLAB West Coast Symposium Sponsored by Novo Nordisk Announced
Sep 05, 2017
Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices
Jun 20, 2017
Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes